Last reviewed · How we verify

NCT04633915: COV-HD

Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.

Completed Last updated 3 August 2021
What this trial tests

trial in Dialysis in 51 participants. Completed in 18 July 2021.

Timeline
26 November 2020
Primary endpoint
18 July 2021
18 July 2021

Quick facts

Lead sponsorSaint Petersburg State University, Russia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment51
Start date26 November 2020
Primary completion18 July 2021
Estimated completion18 July 2021
Sites1 location across Russia

Conditions studied

Sponsor

Saint Petersburg State University, Russia

Who can join

18 and older, any sex, with Dialysis or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is prospective cohort study aimed to compare antibody response against SARS-CoV-2 in dialysis patients and non-dialysis-dependent volunteers. The research hypothesis is that dynamic of IgG antibodies against SARS-CoV-2 will differ in two groups. To determine whether there is a statistically significant interaction between factors "group" and "time" on the titer of IgG antibodies against SARS-CoV-2, a two-way repeated measures ANOVA will be used.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dialysis

Currently open trials in the same condition.

Other Saint Petersburg State University, Russia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04633915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing